Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Adupa P. Rao"'
Publikováno v:
Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-9 (2021)
Abstract Background Cystic fibrosis (CF) patients present with a variety of symptoms, including mood and cognition deficits, in addition to classical respiratory, and autonomic issues. This suggests that brain injury, which can be examined with non-i
Externí odkaz:
https://doaj.org/article/4161687e54964a8c9bd653b1b7e664a6
Autor:
Shane Shahrestani, Tzu-Chieh Chou, Kuang-Ming Shang, Gabriel Zada, Zea Borok, Adupa P. Rao, Yu-Chong Tai
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract Pulmonary function testing (PFT) allows for quantitative analysis of lung function. However, as a result of the coronavirus disease 2019 (COVID-19) pandemic, a majority of international medical societies have postponed PFTs in an effort to m
Externí odkaz:
https://doaj.org/article/26d8cbf496d3407cb3507c8887d87206
Autor:
Eunjin Hong, Eugeniu Carmanov, Alan Shi, Peter S. Chung, Adupa P. Rao, Kevin Forrester, Paul M. Beringer
Publikováno v:
Pharmaceutics, Vol 15, Iss 5, p 1438 (2023)
Elexacaftor/tezacaftor/ivacaftor (ETI) treatment has potential benefits in lung transplant recipients, including improvements in extrapulmonary manifestations, such as gastrointestinal and sinus disease; however, ivacaftor is an inhibitor of cytochro
Externí odkaz:
https://doaj.org/article/5554101f956f44a4aaf97ee484c7fd66
Autor:
Eunjin Hong, Regina Li, Alan Shi, Lisa M. Almond, Joshua Wang, Amin Z. Khudari, Soumar Haddad, Sarkis Sislyan, Marissa Angelich, Peter S. Chung, Adupa P. Rao, Paul M. Beringer
Publikováno v:
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 43:291-299
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::314951fb4c28a46424a25ec52bce3c26
https://doi.org/10.1002/phar.2786
https://doi.org/10.1002/phar.2786
Publikováno v:
Open Journal of Respiratory Diseases. 11:19-25
Rationale: Survival and longevity in patients with cystic fibrosis (CF) have improved with new treatments, so that pregnancy can be safely undertaken despite physiologic limitations. Dyspnea still develops in the latter stages of pregnancy. To explai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::01930915acdcfd66ee559923eecd6670
https://doi.org/10.4236/ojrd.2021.111002
https://doi.org/10.4236/ojrd.2021.111002
Publikováno v:
Clinical pharmacology and therapeutics. 111(6)
Cystic fibrosis transmembrane conductance regulator (CFTR) modulating therapies, including elexacaftor-tezacaftor-ivacaftor, are primarily eliminated through cytochrome P450 (CYP) 3A-mediated metabolism. This creates a therapeutic challenge to the tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a947c2bcb49cb91b6ab88fc5a38a30ea
https://pubmed.ncbi.nlm.nih.gov/35292968
https://pubmed.ncbi.nlm.nih.gov/35292968
Publikováno v:
Journal of translational medicine, vol 19, iss 1
Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-9 (2021)
Journal of Translational Medicine
Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-9 (2021)
Journal of Translational Medicine
Background Cystic fibrosis (CF) patients present with a variety of symptoms, including mood and cognition deficits, in addition to classical respiratory, and autonomic issues. This suggests that brain injury, which can be examined with non-invasive m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc12a03f48f4927bf7c5ef3ed4e722a3
https://escholarship.org/uc/item/4842v7kr
https://escholarship.org/uc/item/4842v7kr
Publikováno v:
Pharmacotherapy. 39(6)
INTRODUCTION Oral azithromycin (AZM) has been shown to reduce airway inflammation and disrupt biofilm formation. However, chronic AZM therapy may result in QT interval (QTc) prolongation. OBJECTIVES The goals of this study were twofold: (i) to charac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08c68b6aec00832cc6e0481f6b6ac440
https://pubmed.ncbi.nlm.nih.gov/31045258
https://pubmed.ncbi.nlm.nih.gov/31045258
Autor:
Paul M. Beringer, Jordanna G. Jayne, David Z. D'Argenio, Adupa P. Rao, Joshua Wang, Park Ayj, Lynn Fukushima
Publikováno v:
Antimicrobial Agents and Chemotherapy. 62
Over the past decade, the prevalence of infections involving methicillin-resistant Staphylococcus aureus (MRSA) in patients with cystic fibrosis (CF) has increased significantly. Tedizolid (TZD) demonstrates excellent activity against MRSA and a favo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74832706c15b214c4a10b3f3cd52dae2
https://doi.org/10.1128/aac.00550-18
https://doi.org/10.1128/aac.00550-18
Autor:
Joshua Wang, David Z. D'Argenio, Paul M. Beringer, Adupa P. Rao, Timothy J. Bensman, Lynn Fukushima, Jordanna G. Jayne
Publikováno v:
Antimicrobial Agents and Chemotherapy. 61
Acute pulmonary exacerbations (APE) involving Pseudomonas aeruginosa are associated with increased morbidity and mortality in cystic fibrosis (CF) patients. Drug resistance is a significant challenge to treatment. Ceftazidime-avibactam (CZA) demonstr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2b92f7cb2a6848cee52edd9fe5e72b9
https://doi.org/10.1128/aac.00988-17
https://doi.org/10.1128/aac.00988-17